JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - NUVATION BIO INC
Hi, everyone. My name is Farzeen Haque, one of the biotech analysts at Jefferies. It's my pleasure to introduce David Haque CEO and Philip Sauvage, CFO of Navation Bio. Maybe David, you can start off giving a quick one-minute intro to the company. Yes. So we have, I guess, focus on three programs. So Ibtrozi is a commercial stage asset approved a year ago in the United States, also approved in China, Japan, and about to be approved in Europe. We've had about a year of sales, and we are already a market leader in our space. We are also a market reader in first-line patients. If you look at our quarter-on-quarter growth in the last quarter, it was up 18% in spite of a 20% drop in new patient alerts in testing for RASP1. So I would say we're about $100 million for the year so far. and I think that if you look at our data our 90% response rate and 50 month duration of response have not been matched by anyone in the first line space in the second line indication our 56% response weight and 66% intracranial response rate have not been matched by anyone. In the second indication our tolerability and safety we are now the only brain penetrant RAS1 TKI that does not have a CNS warnings and precautions. So I would say that that program is going very well. Our second program, safucitinib, is a mutant IDH1 glioma drug. We are in four studies right now. Unlike the only competitor in the space, voracitinab, which is approved only in the low-grade glioma indication, we have shown activity in both low-graded and high-grade glioma. If you look at voracitinib's most recent three-year data, in the low-grade indication, their response rate was 21%. In the same indication, our response rate Was 52%. If you Look at their progression-free survival at three years, in the low rate indication, it was 52% PFS, ours was 79%. So we think that this drug is extremely active in the low-rate indication. If you look at voracitinib's response in high-grade glioma, it was zero. Ours was 17%, with a third of those being complete responses. So again, we believe that sapucitinab is extremely active in low-grade setting as well as the high-rate setting. We're in a number of trials. Our earliest data we'll read out in 2027. We're going to see grade 3 oligo patients, a form of high-grade glioma, that we'll start to have data in in the second half of next year. We're also enrolling patients in a post-voracitinib failure indication. That's clearly a really big indication, and we'll also have some data in that indication probably in the 2nd half of the next year, and then we have 2 other trials we're reading out with the PFS endpoint later on in 2029 but our first data on response rate will start to read out in the second half of next year we believe that if you look at the precedent set by companies like chimerics where their drug was approved on 11 responses and 50 patients we think you know 20% or so response rate or higher is potentially sufficient to to get approval in an indication where there is no other therapy. And given the activity that we've seen with Safflu set up in both the low-grade and high-grade indications, we think that we're very bullish on that program. Our third program is a drug-drug conjugate program. DDCs are like an ADC without the A, so no antibody. We're fusing two small molecules together. Because small molecules are so much smaller than antibodies, They can go places that antibodies can't go, and they can also do things that antibodies and antibody drug conscience can't do. I think a very exciting example of the DDC, actually the only company that we are aware of that has a program like ours, is Halda. As you know, Halda's prostate drug, based on 10 patients of data, was acquired for $3 billion, and they just recently announced post-extending response rates of 69%. Their molecule is basically a DDC. We have an entire platform based around this DDC concept, and we're going to be making an announcement on that program in the next six weeks or so, a very brief announcement, and then we're gonna follow that up with an R&D day earlier next year. So we think that's an extremely exciting platform technology that could yield many molecules to the pipeline. Makes sense. I want to start with the cefacitinib because I think that's the clear value driver in the future. So if it works across the newly diagnosed, recurrent, high-grade, post-fora, how should we think about the addressable patient population? Which one is the biggest driver for the commercial opportunity? So if you look at the division of low-gradient high-graded glioma among brain tumors, it's about 50-50. But the difference is, IDH1 mutations make patients actually live longer. So if you look at the progression-free survival of IDH2 mutant brain tumors, it's actually extremely long compared to non-IDH1 driven. But IDH4 is also relentless, so they will always continue to grow. So low-grade patients can live 20 plus years. Even high-grade IDH1 mutants, like astrocytoma, even GBM, they can still live six plus years, unlike regular GBM. So what's unique about IDH-1 as a mutation is that it makes the tumor relentless, but it also makes the patient survive for long periods of time. So you do need to treat these tumors, especially when they occur in younger patients. And they will grow relentlessly. They will compromise things like your neurostatus, your vision, your hearing, all the things that you expect brain tumors to do. So it's very important that you address it. You can't give repeated surgeries to young patients. You can'T just keep cutting out parts of the brain. You can' t continually give radiotherapy, which is clearly very damaging to brain tissue. You can''t give chemotherapy. No patient wants to take chemotherapy forever. So you do need an oral therapy. We think our once-a-day pill is a very attractive option, and we can show that we continue to have the results that we've shown so far. So the reason the market opportunity is so large is because when you have 20 years of patients taking the drug, you're talking about a revenue-stacking opportunity you just don't see in general in oncology. So that's in the low-grade setting. In the high-grade settings, even though it's shorter than low-graded, We're still talking about up to six-plus years in the high-grade setting, so that's still an attractive option. So even though the roughly 50-50 split of high-rate to low-grade is how the indications break out, the longer duration of therapy likely in low-rate indications makes that a more compelling commercial opportunity. Now, when I mentioned earlier that voracitinib has a 21% response rate in low grade, we have a 52% response rate in low-grade. So when people ask us why do we believe this drug will work after voracitinib, well we have 31 percentage points more response rate, in the same indication. So we do believe Safi will work after voraciitinim. We believe that if it works after voraceitin, people will use it after voracyitin and even instead of voraceitiin. So, we actually believe that's the path to get the, you know, the entire glial market. Maybe to rephrase that like mechanistically why should how sapo works differently from bora to give that differential responses you know we've made the point before that um even though they both hit idh1 we've we are seeing activities with sapocitinib that you don't see with boracitinab so boracinib's main adverse event is liver function test abnormalities we don't generally see that if you look at our adverse events even though almost all of them are grade one we do see out of our top seven adverse events, five of them are immune related. So we see things like alopecia, rash, arthralgia like rheumatoid arthritis, pruritus, and we believe that if we look at our responses they take six to twelve months to kick in, sometimes even longer. In fact, even between years two and year three we had an additional eight percent response rate going from 44% to 52% in our recent publication. So when you see those really long times to responses and then really durable responses, so we have a GBM that's been in the CR for three and a half years. We have another high-grade oligo dendroglioma that's gone for two years. When you see really long onset to response and then very durable responses it's very reminiscent of immuno-oncology agents. So we actually believe that sapucitinib has a significant immune component to its activity and we believe that that differentiates it from Vora and why we believe we will see responses after Vora failure and also we're already seeing responses and indications that Vora's response rate is zero. Got it. Any color on the enrollment across Sigma, the oligodendroglioma study and the post-Vora study? So, you know, we haven't given any guidance to the street but I would say that all the studies have been enrolling very well. We've committed publicly that we will have a minimum of 20 grade 3 oligo patients enrolled by this year, and we are absolutely on track for that. If you look at the post-Vora failure study, which is, you know, one of the earlier studies to read out, the reason that's so attractive is that survey has now treated, you now, thousands of patients with Vora. If you looked at the progression rate on Voracitinib, 23% of patients in the and they go study progress at one year. So there are thousands of patients who've already failed VARA and will continue to fail. We believe we need to enroll 50 of those patients and show 10 responses to be in a position to take that to the FDA for a potential consideration of approval. So I think that there are a lot of patients who are failing VARA. That study should enroll very quickly. We're already on track to get the grade three oligos that we've already committed publicly and will probably exceed that target. And so I think that's a testament to how many of these patients there are and the size of the commercial opportunity. Is there a combination of the patient number, confirmed responses, and follow-up for the 20% benchmark that you mentioned, like to have the conversations with the FDA for a path? Yeah, if you look at Chimerics, I think they had 50 patients in their pivotal study. They had 11 responses, 22% response rate, and they were approved. So I think that we've said, you know, what the FDA wants to see is that your confidence interval between your response rate doesn't overlap with the response rate of the other available therapies, which in this case would be chemotherapy with a mid-single-digit response rate. So we do think that somewhere in the ballpark of 20% response is enough to have non-overlapping confidence intervals to get approval. And then, you Know, duration of response needs to be something that FDA considers meaningful. We haven't really talked publicly about what that number is, but I think a lot of people figure that's just a number of months. These are patients who are young. They're progressing relentlessly. They're going to do badly if they're not treated. So I think that's a very, very unmet need. And the data that we've shown, 52% response rate, low rate with 79% PFS at three years, I mean, that certainly would beat the bar, I would think. For the standard of care, is it like more six months for the duration response? You know, I think that people use that number often, but, you know, again, we haven't released. Okay. And then for the post-BORA, you mentioned that it could enroll faster, but you're guiding to both data sets, most likely in second half 27. Yeah, we have not given any guidance on that. I do think that there are thousands of patients at this point who have failed BORA. As I said, we need 50 of them, and we need to see about 20% responses, so hopefully around 10 patients or more, and I thinkthat would do the trick. So, you know, we do think that trial will enroll pretty quickly, and we think that we're already getting lots of inbounds for patients who want to be on SAP. We've just given the data we've presented publicly so far. So I do think there's a lot of interest in that trial, and it will enroll well. Got it. One of the things is that you just mentioned that there's an delayed response sometimes. How could that complicate FDA's interpretation of the efficacy? Could that be? Well, I think whatever response rate we do report, it's only going to get better from there. So, you know, the responses can kick in. I think our earliest response we've ever seen is around two weeks. But most of the responses kick in at six to 12 months. As I mentioned, between years two and year three, we had 8% more responses in our Daiichi study. So these patients can continue to improve for years after their initial responses. So, you know, we do think that we'll take the data that we have next year and start to talk to FDA about that, but we would anticipate whatever number we put out, that will probably improve over the subsequent years. Is there a benchmark similar to 20% or close to that? I think that 20%, you know – we know that chimerics was approved on a 22% response rate, so I think we have to give a precedent that would be a reasonable one. Just to reiterate on what David was doing, the 20% is because of 50 patients, if you want, And that's 10, the 11th of chimerics. But what the FDA wants to see is just separation. So if your response rate is higher, theoretically, they need to see less patients because you just want to see statistical separation from the single-digit response rate of chemo. And that is true for both scenarios, post-Voronigo, just like the great-fuelly-good and Ogeoma, because in both cases, there is nothing else but salvage chemo, too. Makes sense. Okay, so switching gears to Iptrosi. That market is considered, the Ross 1 market is considered niche by many, but how do you see the long-term opportunity unfolding as you have launched into that? So the market is niche in terms of how many new patients are diagnosed a year. It's about 3,000 patients. If you multiply that times the drug price, it's still about a billion dollars a year in the theoretical maximum potential of that opportunity. What's unique about Ross 1 is that with Ibtrozi, our duration of response is 4.2 years. That means that every patient in year one, let's say we have 3,000 patients who get drugged, and that's about a billion. That means everyone in year 1 will likely go to year 2, where you'll have another 3, 000 new patients. So that will stack to 2 billion. By the year 3, you'll add 3 billion. By year 4, you add 4 billion. So even for a 3, 00 patient incidence indication, it's still potentially a pretty large commercial indication because of the revenue stacking. You don't see generally 4.2 years of DOR for most drugs. Most people are pretty happy if your duration of response is in the 6- to 12-month range. So I think that having such a long DOR and a 90% response rate, which has not been matched by many drugs in any oncology indication with any drug, I think makes this a very uniquely attractive commercial opportunity. Okay. And in third quarter, you had a softness with the new patient starts and also with the NGS testing. So is there something, a temporary softness or more of a structural change in how the disease is being diagnosed and treated? You know, so we buy new patient alerts for new ROS1 diagnoses from all the testing labs. And in the last quarter, there was a 20% drop in new alerts. but in rare indications that just just happens we know that there was also a 14% drop in KRAS in this last quarter in the previous quarter there was a 19% drop and out diagnoses when you when you have rare mutations you know 10 patients here or there can really change the the the testing rate the diagnosis rate so we don't think that it's any trend we just think its lumpiness. What's the most important thing is that in spite of a 20% drop in new patient diagnoses in that quarter, we still grew sales 18% in spite of that. Of course, it would have been higher than that had it been 20% more diagnoses, but we still moved over the previous quarter 18%, and we're still market leader, and we are also first-line share leader. So I think we're doing well. Clearly, I think that will equilibrate over time. So we don't expect that that's indicative of any change in how this drug is working or how the disease is being diagnosed. And the community testing remains one of the key upside levers. And now that you're six quarters into the launch, have you seen any measurable increase in the NGS testing with the DNR? So we've made a concerted effort to actually look at centers where testing rates are on the low side. And with our efforts, we've actually we're able to at least have one center double its testing rate and another one triple it. So we actually have made some strides in changing testing rates in large community centers. Academic centers, their testing rate is close to a hundred percent so there's not much room for improvement there but in the community setting there is room for a improvement and especially now in some of these large aggregators where they control many patients in many states, if you can change testing rates there that clearly will have great ramifications for the the product. So we are making a significant effort to educate centers on that, and we have had success in the centers that we've approached. One of the common questions I get is, of course, the GSK market entry. And there seems to be a disconnect, but Iptros is the only one that doesn't have the CNS warning on the label. But do you think that doctors, investors, there's a disconnect? But do You think doctors understand the nuance between the two drugs, their profiles? You know, I think that they need to read the labels. If you look at the, so the GSK drug is approved in the second line setting. If we look at second line response rate of that drug, you know, it's 49%, ours is 56%. So that's the label. If look at intracranial response rate for that drug it's 48% or 66%. So just apples to apples in the 2nd line indication, not really that close and the other thing is that if you look at the on the safety side not only is there a cns warnings and precautions with that but that's with only 14 percent of patients having one year follow-up we have four times that level of follow-ups so adverse events only accumulate with more time so we expect those adverse events to to grow further and if you Look at where we are right now with no cns the warnings and Precautions I think I mentioned previously that out of our toxic top six adverse events out of 337 patients we only had one discontinuation so we think that if it Rosie's efficacy is not only by far the best with a 90% response rate in 50 month duration of response but our safety and tolerability are also have not been matched so we we think we're in a good position so one of the other things is that is a second line label so they're going to expand to a frontline label. We don't know when. We hope maybe 2nd of 27th. And is there any reason to believe that the label will change? If anything, it should get worse. You know, I think the AEs will get worse for sure. And the thing is that even by next year, there won't be the length of follow-up that we have. So no one's going to have a 15-month follow-ups, much less duration of response. Our duration of responses is 15 months. I think it's going be hard to beat. our response rate is 90%. That's going to be hard to beat. So I just think that it's going to be difficult to overtake deutrosy. And you also have the adjuvant study, which they're not running. And what makes you believe that investigators should be interested to enroll the study, and how is that enrollment going? So you make an interesting point that we are actually the only Ros1 TKI being developed in the adjutant setting. In order to be given that early in the treatment of a patient, you have to be incredibly well tolerated. And because we are incredibly well tolerated, that study is enrolling beautifully, and we are going to be the only ROS1 TKI with an adjuvant label, we believe. So, that said, I think that that increases the market even further. I think we've estimated about 30% larger commercial opportunity by moving it to the adjuant setting. And we also, when we look at the RET study with supracatinib, the hazard ratio of 0.17 in the libretto 432 study is really extraordinary and gives us even more confidence that this study will not only be positive, but will actually read out sooner than we actually previously anticipated. So we believe that the RET study, the librettal 432 study is an example of what a great drug does in the adjuvant setting. And we believe that will reflect exactly the same way in the Ibtrozi adjuvant study. Makes sense. So a year from now, hopefully we'll all be back. What would need to be true for you to say that Iptrosi has meaningfully exceeded your expectations? You know, I think if we just see the revenue stacking and the new patient share that we've talked about, I think it's all a first-line game. So whoever wins first line wins the entire thing. So, you know, with our duration of response, we would expect to see that revenue stacking that we're talking about. I think that would make us feel that we've done a good job in executing it. And given the fact that in 12 months we've gone from nothing to majority market share and first-line leader, I think our commercial team has done a great job, and I think we'll continue to execute. Okay. And then on the BD front, so you guys have a strong balance sheet, and then you have successfully integrated the Enherd acquisition. So what is the current appetite and capacity for in-licensing or even like M&A? Well, like you said, Farzin, we have $660 million of cash at the last quarter, which puts us in a very comfortable position. We had enough cash to get to profitability prior to our rates, our convert rates back in June. So that gives us even more firepower. We are going to be very selective, but we're always actively looking. We think it's healthy for any biotech to confront itself to the rest of the market and to see what's out there and how good it can be. and how good it can be as an add-on to your company as well. So we're looking at things. We also have a base of operation in China, which is helpful to look at certain opportunities as well, so we'll see. We've not done anything yet because we didn't find anything which was good for us at the appropriate price, but who knows if we might. And I think, you know, this brutal market conditions in the last few months, I think given the fact that we have so much cash in our balance sheet will further differentiate us from our peer group and I think allow us to look but even more opportunities on the BD front. So I think that's potentially a really interesting opportunity for us. I want to touch on the DDC update that you're going to have by year-end. So any high-level attributes of the platform, like target selection, payloads, and teamwork focus that you can give us? So we're not going to give that level of detail this year, but we intend to givethat level of details in our R&D day in the beginning part of next year. Okay, so this year will be more of a... Just to tell you where we are and what we're doing with the program, because there's been no update for a long time now. So we're going to tell what we do and where the program is, but next year we want to talk in more detail about exactly what we are doing and why and how. So the Halder one that you explained was an interesting one because that led to a lot of stocks being moving because of the data, even in prostate and other ones. But how do you envision in the longer run, Like, would it be more of a BD, or would you develop it in-house? So, I mean, all of our GDCs have been made in- House. Completely. So this was the platform that actually was the basis upon which I found innovation bio in 2018. So we've been thinking about this for a long time. There are many, many things to consider in doing it. The chemistry is quite difficult, but the Haldic molecule is a very good example of how they've coupled an AR molecule to a BET inhibitor, and that molecule has really quite remarkable activity and, as I said, led to a $3 billion acquisition for 10 patients' worth of data. So we think that's a testament to how promising this platform is. We have many, many programs in our DDC platform, and we're going to announce a little bit of the beginning part of that and talk about what we're doing, but we are very excited about the program. We're going clearly try to go where people haven't gone yet because we don't want to be following another program, So we have a pretty exciting platform that we think we're going to start talking about in detail in the first half of next year. We're almost out of time. Maybe to wrap up, we know the cash, but what are the key catalysts that investors should be focused on over the next six to 12 months? I think we should continue to get Trozy sales. I think that we should do well there. Look at SAFU updates. See what the response rate data are in 2027. the DDC update especially with the R&D they'll get more of an understanding of what we're actually doing and why it's so promising and then look for any other, if there's any BD or other opportunities that we decide to bring in-house It's always great chatting with you guys, thank you so much for your time Thanks so much
- Company
- NUVATION BIO INC
- Keywords
- NUVATION BIO INC